|Category||Life Sciences and Biotechnology|
Human natural killer cells (NKs) are part of the innate immune system and can recognized CD48, which was found to be overexpressed by a variety of cancer types. Existing therapies based on primary NK cells are limited by donor availability and short ex-vivo lifespan.
We develop human NK lines which can be grown limitlessly and inexpensively, contributing in the regulation pathway of CD48. Thus, we will reach therapeutic effect with no extra risk of side effects.